Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Enrollment is nearing completion for two Phase 2 clinical trials testing the experimental treatment ELX-02 in people with cystic fibrosis (CF), according to Eloxx Pharmaceuticals, the company developing ELX-02. ... Read more
The Cystic Fibrosis (CF) Foundation awarded a nearly $700,000 contract to Calibr, the drug discovery and development arm of Scripps Research, to support projects aiming to identify compounds that could ... Read more
The Regional Pharmaceutical Procurement Service in Northern Ireland and the National Health Service (NHS) Wales have reached an agreement with Vertex Pharmaceuticals that will allow people with cystic fibrosis ... Read more
The Cystic Fibrosis Foundation (CFF) is celebrating the United States Food and Drug Administration’s decision to approve Trikafta. The therapy — a triple combo based on elexacaftor, tezacaftor, and ivacaftor, which is being ... Read more
John Pirozzi, a representative of Chelsea Financial Services, will participate in the TCS New York City Marathon to raise money for cystic fibrosis research, the company announced. Pirozzi is ... Read more
The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic ... Read more
Care for cystic fibrosis (CF) has improved substantially in recent decades, but there are still challenges ahead, particularly in ensuring that all patients have access to the best available ... Read more